 |
인쇄하기
취소
|
Daewoong wins Albis patent dispute
Daewoong Pharm is expected to achieve more stable revenue in the sale of Albis, a ranitidine product plus bismuth and sucralfate, by winning its patent dispute.
The Korean Intellectual Property Tribunal ruled on March 31 that the controversial process patent of Albis should be patentable in the nullification trial. Albis generated 25 billion won in last year’s sales.
Upon the rule, Albis...
The Korean Intellectual Property Tribunal ruled on March 31 that the controversial process patent of Albis should be patentable in the nullification trial. Albis generated 25 billion won in last year’s sales.
Upon the rule, Albis...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.